- Home
- TREO vs RNAZ Comparison
TREO vs RNAZ Comparison
Compare TREO & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TREO | RNAZ |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 27.9M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TREO | RNAZ |
|---|---|---|
| Price | $1.66 | $1.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 48.8K | 26.1K |
| Earning Date | 11-06-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $1.50 |
| 52 Week High | $5.90 | $12.60 |
Technical Indicators
Market Signals| Indicator | TREO | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 31.62 | 40.48 |
| Support Level | $1.50 | $1.57 |
| Resistance Level | $2.24 | $1.95 |
| Average True Range (ATR) | 0.26 | 0.15 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 29.76 | 24.39 |
Price Performance
Historical ComparisonAbout TREO Tactical Resources Corp. Common Shares
Tactical Resources Corp is an exploration & development company focused on the rare earth elements (REE) that drive the green technologies of the future. Its projects include Lac Ducharme Project, Sierra Blanca Quarry Project, and Peak Project.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.